<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite improvements in HLA typing, <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) continues to impair the results after volunteer unrelated donor bone marrow transplantation (VUD-BMT) in adult patients compared with matched sibling BMT </plain></SENT>
<SENT sid="1" pm="."><plain>Here, the outcome after VUD-BMT using a specific regimen with high-dose anti-T-lymphocyte globulin (ATG) was analysed </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-five adult patients, median age 34 years (range 17-55 years), with <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were transplanted in first complete remission (CR1)/first <z:hpo ids='HP_0011010'>chronic</z:hpo> phase (CP1) (early disease) (n = 21) or in advanced (CR2/CP2, no remission) disease (n = 34) from an unrelated marrow donor </plain></SENT>
<SENT sid="3" pm="."><plain>GVHD prophylaxis consisted of ATG-S (Fresenius) 60-90 mg/kg b.w. prior to transplantation, in addition to <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> and short-course <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Graft failure did not occur and white blood cell count (WBC) &gt; 1.0 x 10(9)/l was reached at median day +16 </plain></SENT>
<SENT sid="5" pm="."><plain>The cumulative incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> (a)GVHD grade II-IV was 15% [95% CI (8%, 28%)] and of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was 51% [95% CI (38%, 68%)] </plain></SENT>
<SENT sid="6" pm="."><plain>The cumulative incidence of relapse within 1 year was 0% [95% CI (0%, 19%)] and 21% [95% CI (11%, 40%)] for patients with early and advanced disease respectively </plain></SENT>
<SENT sid="7" pm="."><plain>With a median follow-up of 28 months (range 16-45 months), 2-year disease-free and overall survival for patients transplanted in CR1/CP1 was 81% and 81% [95% CI (64%, 98%)], respectively, and for patients with advanced disease was 33% [95% CI (17%, 50%)] and 40% [95% CI (23%, 57%)] respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Complete and persistent donor chimaerism was seen in 77.5% of 40 patients evaluated </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 14 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>)-CP1 patients became bcr-abl negative within 250 d </plain></SENT>
<SENT sid="10" pm="."><plain>High-dose ATG pretransplant results in a low incidence of severe aGVHD without compromising donor chimaerism or elimination of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Our results are similar to data obtained after matched sibling donor transplantation </plain></SENT>
</text></document>